India may move away from compulsory licensing

Genéricos/General | Posted 15/03/2013 post-comment0 Post your comment

The Indian Government, in a move that goes away from recent decisions, has suggested that the prices of patented pharmaceutical drugs be controlled by linking them to the country’s per capita income rather than by issuing compulsory licences.

India V13C03

The Department of Pharmaceuticals (DOP) in its new draft policy on price negotiation for patented drugs has suggested that once patented drugs are regulated by the government, the provision to issue compulsory licences on the basis of unaffordability of drugs will not be possible.

In its draft policy the DOP has stated that ‘once a government appointed committee goes for some form of price regulation of patented medicines and fixes a price of the medicines which is accepted by the government, this fixed price would be supposed to be reasonable and hence it will not be possible for the government to use the tool of compulsory licence on the ground of reasonableness of the price of the patented medicine.’ However, it added that the provision for issuing compulsory licences on other grounds, apart from price, will still remain.

India issued its first compulsory licence in March 2012, allowing India-based drugmaker Natco Pharma to launch a generic version of Bayer’s liver and kidney cancer drug Nexavar (sorafenib).

Current pricing control in India is based on production costs for drugs and covers 74 active pharmaceutical ingredients (APIs) and about 1,577 finished formulations in the country’s National List of Essential Medicines.

The new policy by the DOP aims to ensure the availability of essential medicines, i.e. those on the National List of Essential Medicines, at reasonable prices, while still providing sufficient opportunity for innovation and competition to support the growth of industry.

Editor’s comment
Is the Indian Government going down the right path with this proposal?  Is compulsory licensing in India a better way to ensure access to essential medicines?

Please feel free to share your thoughts via email or in the comments section below. Should India keep the compulsory licensing policy? Or is it making the right decision to move toward pricing controls instead?

Related articles

India issues more compulsory licences

Bayer opposes sorafenib compulsory licence in India

PhRMA speaks out against compulsory licensing in India

Reference

1.  GaBI Online - Generics and Biosimilars Initiative. Indian government issues first compulsory licence [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Mar 15]. Available from: www.gabionline.net/Generics/General/Indian-Government-issues-first-compulsory-licence

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: DOP, The Economic Times India

comment icon Comments (0)
Post your comment
Related content
FDA closes Zhejiang Huahai Pharmaceutical warning letter
Application V15a16
Genéricos/General Posted 19/11/2021
FDA reaches 100 generic approvals
53 MD002445
Genéricos/General Posted 12/11/2021
New five-year medicines agreements in Australia
24-AA011041
Genéricos/General Posted 24/09/2021
Generics applications under review by EMA – July 2021
EMA logo 2 V13F14
Genéricos/General Posted 23/07/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010